NewsBenzingaSupernus Pharmaceuticals eleva su previsión de ventas para el ejercicio fiscal 2026 de $860.000M-$890.000M a $875.000M-$900.000M frente a los $877.738M estimados Supernus Pharmaceuticals eleva su previsión de ventas para el ejercicio fiscal 2026 de $860.000M-$890.000M a $875.000M-$900.000M frente a los $877.738M estimados Benzinga 2026.10.29 20:17 (GMT+0) Open on Benzinga Other news CORRECTION: Alignment Healthcare Raises FY2026 Sales Guidance from $5.195B-$5.225B to $5.245B vs $5.218B Est CORRECTION: Alignment Healthcare Sees Q4 Sales $1.316B vs $1.335B Est GATX Corporation (GATX) Q3 2026 Earnings Call Transcript Grupo Televisa Q3 EPS $0.09 Beats $0.03 Estimate, Sales $815.845M Miss $837.810M Estimate West Bancorporation, Inc. (WTBA) Q3 2026 Earnings Call Transcript Canaccord Genuity Maintains Buy on Wave Life Sciences, Raises Price Target to $44
CORRECTION: Alignment Healthcare Raises FY2026 Sales Guidance from $5.195B-$5.225B to $5.245B vs $5.218B Est
